← Companies|Hyku Bio
Hy

Hyku Bio

Cambridge MAFounded 202115 employees
Private CapbiotechPrivateOncology
Platform: Targeted IFN
Market Cap
N/A
All Drugs
2
Clinical Trials
2
Failed / Terminated
0
FDA Approved
0
Drug Pipeline (2 programs)
Drug NameCodePhaseTrialsModalityTargetMOAIndications
GozenesiranHYK-8771NDA/BLA1siRNAPARPBCMA ADCLGSPTSD
HYK-8507HYK-8507Phase 11Fusion ProteinGLP-1RBiTEWMGBM
Financial Documents
This is a private company — SEC filings are not available.
Catalyst Events (1)
2029-12-12
HYK-8507 Interim
Cholangiocarcinoma
Interim